Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Early Time Courses of Recurrent Thromboembolism and Bleeding during Apixaban or Dalteparin Therapy for Patients with Cancer

Katherine J. Creeper, Alexander T Cohen, Raza Alikhan, Jean M. M Connors, Menno V Huisman, Andres Munoz, Giorgio Vescovo, Rupert Bauersachs, Giancarlo Agnelli, Cecilia Becattini

Blood (2022) 140 (Supplement 1): 8515–8517.

https://doi.org/10.1182/blood-2022-168115

Published: 2022

Journal Articles

Comparison of Rivaroxaban and Low Molecular Weight Heparin in the Treatment of Cancer-Associated Venous Thromboembolism

Craig I. Coleman, Kimberly Snow Caroti, Khaled Abdelgawwad, George Psaroudakis, Marcela Rivera, Gunnar Brobert, Alexander T. Cohen, Alok A. Khorana, Cecilia Becattini, Agnes Y. Lee, Anders Ekbom, Marc Carrier

Blood (2022) 140 (Supplement 1): 11368–11369.

https://doi.org/10.1182/blood-2022-166949

Published: 2022

Journal Articles

Effectiveness and Safety of Anticoagulants in Cancer Patients with VTE and Kidney Disease

Alexander T Cohen, Virginia Noxon, Amol D Dhamane, Shrushti Shah, Dionne M Hines, Tamuno Alfred, Jose Chaves, Xuemei Luo

Blood (2022) 140 (Supplement 1): 10853–10854.

https://doi.org/10.1182/blood-2022-163272

Published: 2022

Journal Articles

Rivaroxaban Versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism: A Head-to-Head Analysis of the United States Cohort of the Observational Study in Cancer-Associated Thrombosis for Rivaroxaban: (H2H-OSCAR-US)

Kimberly Snow Caroti, Khaled Abdelgawwad, George Psaroudakis, Marcela Rivera, Gunnar Brobert, Alexander T Cohen, Alok A Khorana, Cecilia Becattini, Agnes Y. Lee, Anders Ekbom, Marc Carrier, Craig I. Coleman

Blood (2022) 140 (Supplement 1): 1257–1258.

https://doi.org/10.1182/blood-2022-167801

Published: 2022

Journal Articles

Effectiveness and Safety of Apixaban Vs Warfarin Among Venous Thromboembolism Patients Using Five US Databases: A Subgroup Analysis of Obesity

Alexander T Cohen, MBBS MSc MDFRACP FESC, Janvi Sah, MS, Theodore Lee, MD, Gail Wygant, RN, Lisa Rosenblatt, MD MPH, Patrick Hlavacek, MPH, Birol Emir, PhD, Allison Keshishian, MPH, Rachel Delinger, MPH, Xuemei Luo, PhD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-140453

Published: 2020

Journal Articles

Patient Preferences Regarding Anticoagulation Therapy in Patients with Cancer Having a VTE Event - a Discrete Choice Experiment in the Cosimo Study

Nils Picker, MSc, Alexander T Cohen, MBBS, MSc, MD, Anthony Maraveyas, MD PhD, Jan Beyer-Westendorf, MD, Agnes Yuet Ying Lee, MD MSc, FRCPC, Lorenzo G Mantovani, Yoriko De Sanctis, MS, Khaled Abdelgawwad, Samuel Fatoba, Miriam Bach, Thomas Wilke, Prof. Dr. rer. oec.

Blood (2019) 134 (Supplement_1): 2159.

https://doi.org/10.1182/blood-2019-128095

Published: 2019

Journal Articles

Baseline Characteristics and Clinical Outcomes from the Cancer Associated Thrombosis - Patient Reported Outcomes with Rivaroxaban (COSIMO) Trial

Anthony Maraveyas, MD PhD, Jan Beyer-Westendorf, MD, Agnes Yuet Ying Lee, MD MSc, FRCPC, Lorenzo G Mantovani, Yoriko De Sanctis, MS, Khaled Abdelgawwad, Samuel Fatoba, Miriam Bach, Alexander T Cohen, MBBS, MSc, MD

Blood (2019) 134 (Supplement_1): 2161.

https://doi.org/10.1182/blood-2019-126810

Published: 2019

Journal Articles

Rivaroxaban and Extended Thromboprophylaxis in Acutely Ill Medical Patients with History of Cancer: Insights from the Magellan and Mariner Studies

Alex C. Spyropoulos, MD, Concetta Lipardi, MD PhD, Alexander T Cohen, MBBS, MSc, MD, Biljana Vučković, MD PhD, Jianfeng Xu, PhD, Wentao Lu, PhD, Theodore E. Spiro, MD, Elliot S. Barnathan, MD, Gary E. Raskob, PhD

Blood (2019) 134 (Supplement_1): 3671.

https://doi.org/10.1182/blood-2019-122945

Published: 2019

Journal Articles

Association of Bleeding Severity with Mortality with in-Hospital and Extended Thromboprophylaxis in the Medically Ill in the Magellan Trial

Alex C. Spyropoulos, MD, Gary E. Raskob, PhD, Alexander T Cohen, MBBS, MSc, MD, Walter Ageno, Jeffrey I. Weitz, MD, Theodore E. Spiro, MD, Wentao Lu, PhD, Concetta Lipardi, MD PhD, Elliot S. Barnathan, MD

Blood (2019) 134 (Supplement_1): 2441.

https://doi.org/10.1182/blood-2019-122930

Published: 2019

Journal Articles

Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magellan Study

Gary E. Raskob, PhD, Alex C. Spyropoulos, MD, Alexander T Cohen, MBBS, MSc, MD, Jeffrey I. Weitz, MD, Walter Ageno, Yoriko De Sanctis, MS, Wentao Lu, PhD, Jianfeng Xu, PhD, John Albanese, BS, MBA, Chiara Sugarmann, BSN, MSHS, Concetta Lipardi, MD PhD, Theodore E. Spiro, MD, Elliot S. Barnathan, MD

Blood (2019) 134 (Supplement_1): 163.

https://doi.org/10.1182/blood-2019-122934

Published: 2019

Journal Articles

Safety and Effectiveness of Apixaban, LMWH, and Warfarin Among Venous Thromboembolism Patients with Active Cancer: A Retrospective Analysis Using Four US Claims Databases

Alexander T Cohen, MBBS, MSc, MD, Allison Keshishian, Theodore Lee, MD, Gail Wygant, RN, MS, Lisa Rosenblatt, MD MPH, Patrick Hlavacek, MPH, Jack Mardekian, PhD, Daniel Wiederkehr, MPH, Janvi Sah, MS, Xuemei Luo, PhD

Blood (2019) 134 (Supplement_1): 326.

https://doi.org/10.1182/blood-2019-121769

Published: 2019

Journal Articles

Safety and Effectiveness of Apixaban, LMWH and Warfarin Among Venous Thromboembolism (VTE) Patients with Active Cancer: A Subgroup Analysis of VTE Risk Scale

Blood (2019) 134 (Supplement_1): 327.

https://doi.org/10.1182/blood-2019-126931

Published: 2019

Journal Articles

Medically Ill Patients with Moderate Renal Insufficiency Have More Thrombotic and Bleeding Events Than Those with Normal Renal Function: Insights from the Magellan and Mariner Trials of Extended Thrombprophylaxis

Jeffrey I. Weitz, MD, Gary E. Raskob, PhD, Alex C. Spyropoulos, MD, Alexander T Cohen, MD, Theodore E. Spiro, MD, Yoriko De Sanctis, MS, Jianfeng Xu, PhD, Eunyoung Suh, PhD, Wentao Lu, PhD, Concetta Lipardi, MDPhD, Elliot S. Barnathan, MD

Blood (2018) 132 (Supplement 1): 1236.

https://doi.org/10.1182/blood-2018-99-111911

Published: 2018

Journal Articles

Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients

Noémie Kraaijpoel, MSc, Nick van Es, MD, Suzanne M Bleker, MD, Marjolein P Brekelmans, MD, Elise S Eerenberg, MD, Saskia Middeldorp, MD PhD Professor of MDcine, Alexander T Cohen, MBBS MSc MD, Harry R Büller, MD PhD

Blood (2016) 128 (22): 2611.

https://doi.org/10.1182/blood.V128.22.2611.2611

Published: 2016

Journal Articles

The Safety and Efficacy of Full Versus Reduced Dose Betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention with Extended Duration Betrixaban (APEX) Trial

Alexander T Cohen, MBBS MSc MD, Rim Halaby, MD, Serge Korjian, MD, Yazan Daaboul, MD, Donald Szlosek, Douglas Arbetter, MPH, Samuel Z. Goldhaber, MD, Russell Hull, MBBS, Adrian Hernandez, MD, Alexander Gold, MD, Brian Wiens, PhD, Robert Harrington, MD, C. Michael Gibson, MD

Blood (2016) 128 (22): 3824.

https://doi.org/10.1182/blood.V128.22.3824.3824

Published: 2016

Journal Articles

Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use

Ida Martinelli, Anthonie W. A. Lensing, Saskia Middeldorp, Marcel Levi, Jan Beyer-Westendorf, Bonno van Bellen, Henri Bounameaux, Timothy A. Brighton, Alexander T. Cohen, Mila Trajanovic, Martin Gebel, Phuong Lam, Philip S. Wells, Martin H. Prins

Blood (2016) 127 (11): 1417–1425.

https://doi.org/10.1182/blood-2015-08-665927

Published: 2016

Journal Articles

Predictors of Major Bleeding in Patients with First Venous Thromboembolism Treated with Vitamin K Antagonists in Clinical Practice in the United Kingdom

Alexander T Cohen, MBBS MSc MD, Christopher Wallenhorst, MSc, Anja Katholing, MSc, Melissa Hamilton, MPH, Sreevalsa Unniachan, MBBS MPH, Carlos Martinez, MDMSc

Blood (2015) 126 (23): 2327.

https://doi.org/10.1182/blood.V126.23.2327.2327

Published: 2015

Journal Articles

How I manage venous thromboembolism risk in hospitalized medical patients

Mark Dobromirski, Alexander T. Cohen

Blood (2012) 120 (8): 1562–1569.

https://doi.org/10.1182/blood-2012-03-378901

Published: 2012

Journal Articles

The MAGELLAN Study: An Analysis of Outcomes Utilizing D-Dimer

Alexander T Cohen, Theodore E Spiro, Paul Burton, Harry R Büller, Lloyd Haskell, Da-Yi Hu, Russell D Hull, Alexandre Mebazaa, Geno J Merli, Sebastian Schellong, Alex C Spyropoulos, Victor F Tapson

Blood (2011) 118 (21): 542.

https://doi.org/10.1182/blood.V118.21.542.542

Published: 2011

Journal Articles

An Adaptive-Design Dose-Ranging Study of PD 0348292, a New Oral Factor Xa Inhibitor, for Thromboprophylaxis after Total Knee Replacement Surgery.

Alexander T Cohen, MBBS, MSc, MD, FRACP, Donald Armstrong, BSc., MD, FRCSC, Tadeusz Gazdzik, MD, Camilla Ryge, MD, PhD, Raphael Pak, PhD, Jaap Mandema, PhD, Rebecca Boyd, PhD, Scott McBride, MA, Lorenzo A. DiCarlo, MD

Blood (2008) 112 (11): 980.

https://doi.org/10.1182/blood.V112.11.980.980

Published: 2008

NARROW

Early Time Courses of Recurrent Thromboembolism and Bleeding during Apixaban or Dalteparin Therapy for Patients with Cancer

Comparison of Rivaroxaban and Low Molecular Weight Heparin in the Treatment of Cancer-Associated Venous Thromboembolism

Effectiveness and Safety of Anticoagulants in Cancer Patients with VTE and Kidney Disease

Rivaroxaban Versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism: A Head-to-Head Analysis of the United States Cohort of the Observational Study in Cancer-Associated Thrombosis for Rivaroxaban: (H2H-OSCAR-US)

Effectiveness and Safety of Apixaban Vs Warfarin Among Venous Thromboembolism Patients Using Five US Databases: A Subgroup Analysis of Obesity

Patient Preferences Regarding Anticoagulation Therapy in Patients with Cancer Having a VTE Event - a Discrete Choice Experiment in the Cosimo Study

Baseline Characteristics and Clinical Outcomes from the Cancer Associated Thrombosis - Patient Reported Outcomes with Rivaroxaban (COSIMO) Trial

Rivaroxaban and Extended Thromboprophylaxis in Acutely Ill Medical Patients with History of Cancer: Insights from the Magellan and Mariner Studies

Association of Bleeding Severity with Mortality with in-Hospital and Extended Thromboprophylaxis in the Medically Ill in the Magellan Trial

Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magellan Study

Safety and Effectiveness of Apixaban, LMWH, and Warfarin Among Venous Thromboembolism Patients with Active Cancer: A Retrospective Analysis Using Four US Claims Databases

Safety and Effectiveness of Apixaban, LMWH and Warfarin Among Venous Thromboembolism (VTE) Patients with Active Cancer: A Subgroup Analysis of VTE Risk Scale

Medically Ill Patients with Moderate Renal Insufficiency Have More Thrombotic and Bleeding Events Than Those with Normal Renal Function: Insights from the Magellan and Mariner Trials of Extended Thrombprophylaxis

Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients

The Safety and Efficacy of Full Versus Reduced Dose Betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention with Extended Duration Betrixaban (APEX) Trial

Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use

Predictors of Major Bleeding in Patients with First Venous Thromboembolism Treated with Vitamin K Antagonists in Clinical Practice in the United Kingdom

How I manage venous thromboembolism risk in hospitalized medical patients

The MAGELLAN Study: An Analysis of Outcomes Utilizing D-Dimer

An Adaptive-Design Dose-Ranging Study of PD 0348292, a New Oral Factor Xa Inhibitor, for Thromboprophylaxis after Total Knee Replacement Surgery.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only